Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

According to data from a multicenter evaluation of patients who received their first HCT, late acute GVHD—defined as de novo acute GVHD presenting beyond 100 days after allogeneic HCT—was more severe than classic acute GVHD and showed a lower overall response rate at day 28. Advanced age, female-to-male sex mismatch, and the use of reduced intensity conditioning were associated with development of late acute GVHD, while the use of post-transplant cyclophosphamide-based GVHD prevention was protective.